



BioLight Life Sciences Ltd.

(the “Company”)

December 28, 2023

Re: DiagnosTear Ltd. (Subsidiary) – Receipt of grant from the Israeli Innovation Authority

BioLight hereby announces that its subsidiary, Diagnostear Ltd. ("Diagnostear")¹ that develops the TeaRx™ Technology designed for the identification, diagnosis, adjustment of treatment, and follow-up of diseases in the front of the eye by examining the composition of the tear fluid, has informed it that it has received approval for a financial grant from the Israeli Innovation Authority in the amount of approximately NIS 1 million (the "**Approval**") for the development by it of the second indication of TeaRx™ technology for differential diagnosis of red eye (infections in the front of the eye caused by viruses and/or allergic conjunctivitis).

Royalties shall be paid out of Diagnostear's revenues from sales, if any, as specified in the Approval. In addition, the Approval is subject to a number of obligations, limitations and condition precedents , as is customary in such approvals².

As Company was informed, Diagnostear sees obtaining the such Approval from the Israeli Innovation Authority as an expression of confidence in the clinical need, development feasibility and marketing potential of the product for diagnosing red eye.

About BioLight

BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects in the field of eye diseases and ocular treatments. BioLight's portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine designed to

¹ A subsidiary that is held 74% by the Company

² Including, without derogating from the generality of the aforesaid, proof of supplementary fund raise capability of approximately NIS 1.7 million.

improve the efficacy and safety of treatments of eye diseases exemplifying the enormous potential of Israeli innovation in these fields.

***Forward Looking Statement** The information and details contained in this report including in connection with the actual receipt of grant funds and the development of the of the product for diagnosing red eye as well as predictions, deadlines, assessments and/or plans of the Company and/or Diagnostear in connection with the aforementioned, are "Forward-looking information" as defined in the Israeli Securities Law, 1968-5778 which involves high uncertainty, and is based, among other things, on third parties and on many variables over which the Company and/or Diagnostear do not necessarily have control, and therefore it is possible that the aforementioned information and estimates, in practice will not be realized and/or will not be fully realized and/or will be realized in a materially different way than was initially estimated or observed, including as a result of any of the risk factors as detailed in Section 4.27 in Chapter A of the Company's 2022 annual report, which may have a significant effect, together and separately, on the Company's estimates as mentioned above.*

Free translation: non-binding.

This is a translated version of the Company's immediate report in Hebrew as filed with the Israeli SEC – created for convenience purposes only. In case of contradiction, the Hebrew version will take precedence.